Becton Dickinson & Co. PT Raised to $110.00 at Canaccord Genuity (BDX)
Canaccord Genuity increased their target price on shares of Becton Dickinson & Co. (NYSE:BDX) from $108.00 to $110.00 in a research note issued on Friday, ARN reports. Canaccord Genuity’s price objective would suggest a potential downside of 2.31% from the company’s current price.
Becton Dickinson & Co. (NYSE:BDX) opened at 112.60 on Friday. Becton Dickinson & Co. has a one year low of $94.25 and a one year high of $118.77. The stock’s 50-day moving average is $114.3 and its 200-day moving average is $110.7. The company has a market cap of $21.734 billion and a P/E ratio of 23.57.
Becton Dickinson & Co. (NYSE:BDX) last released its earnings data on Thursday, May 1st. The company reported $1.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.50 by $0.05. The company had revenue of $2.07 billion for the quarter, compared to the consensus estimate of $2.09 billion. During the same quarter in the previous year, the company posted $1.39 earnings per share. The company’s revenue for the quarter was up 3.6% on a year-over-year basis. Analysts expect that Becton Dickinson & Co. will post $6.23 EPS for the current fiscal year.
BDX has been the subject of a number of other recent research reports. Analysts at ISI Group raised their price target on shares of Becton Dickinson & Co. from $123.00 to $130.00 in a research note on Monday, April 7th. They now have a “buy” rating on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Becton Dickinson & Co. in a research note on Wednesday, March 26th. They now have a $120.00 price target on the stock. Finally, analysts at Raymond James upgraded shares of Becton Dickinson & Co. from an “underperform” rating to a “market perform” rating in a research note on Wednesday, February 5th. One research analyst has rated the stock with a sell rating, six have given a hold rating and eight have issued a buy rating to the company’s stock. Becton Dickinson & Co. has an average rating of “Hold” and an average target price of $107.07.
Becton, Dickinson and Company (NYSE:BDX) is a global medical technology company engaged in the development, manufacture and sale of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.